NL-OMON39500已完成不适用
Follow up ALIFE study - Follow up ALIFE
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 364
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •participation in the previously performed ALIFE study (Kaandorp, NEJM, 2010)
排除标准
- 未提供
研究者
相似试验
已完成
不适用
TWICE-Follow up studyprimary osteoporosisJPRN-UMIN000046026Sanzai Hospital82
进行中（未招募）
不适用
The effect of ALFALIFE™ in reducing low-grade inflammatioow-grade inflammationNutritional, Metabolic, EndocrineChronic low-grade inflammationISRCTN12319920Digitcal S.r.l.24
已完成
不适用
The follow up study of "Phase l / ll Study of S-1+oxaliplatin (SOX)+cetuximab as first Line therapy in metastatic colorectal cancer with EGFR-detectable and KRAS wild type (JACCRO CC-06)".metastatic colorectal cancerJPRN-UMIN000027014Japan Clinical Cancer Research Organization33
进行中（未招募）
1 期
ong-term efficacy and safety study to evaluate DX-2930 in preventing angioedema attacks in patients with Type I and Type II hereditary angioedema (HAE)Type I and Type II Hereditary Angioedema (HAE)MedDRA version: 23.1Level: LLTClassification code 10075280Term: Hereditary angioedema attackSystem Organ Class: 100000004850EUCTR2015-005255-27-ITDYAX CORP.212
进行中（未招募）
1 期
ong-term efficacy and safety study to evaluate DX-2930 in preventing angioedema attacks in patients with Type I and Type II hereditary angioedema (HAE)Type I and Type II Hareditary Angioedema (HAE)MedDRA version: 20.0Level: LLTClassification code 10075280Term: Hereditary angioedema attackSystem Organ Class: 100000004850EUCTR2015-005255-27-DEDyax Corp., (an indirect, wholly-owned subsidiary of Shire plc.)225